Clinical data (STEP 4) shows that stopping Wegovy leads to weight regain within 12 months in most patients, because the underlying biology that caused the excess weight resumes once the medication is cleared
No increase in number of adverse events with increasing renal or hepatic impairment was observed, and no new safety or tolerability findings with cagrilintide were identified with renal or hepatic impairment
Developed by a team of top Equinox Coaches, this comprehensive guide covers weight loss on GLP-1 in detail, including topics like drug background, risk efficacy, relapse management, fat loss programming for exercise, and habit development
The dosage may need to be reduced or stopped entirely if this condition develops
Semaglutide Dose Ranges and Weight Loss Outcomes Research from the STEP clinical trials demonstrated that weekly semaglutide doses of 0.5 mg, 1.0 mg, and 2.4 mg produced dose-dependent weight loss, with average reductions ranging from 5% to 18% of baseline body weight over 68 weeks
Pediatric protocols may use weight-based calculations